Literature DB >> 23968988

The Familial Tasmanian Haematological Malignancies Study (FaTHMS): its origins, its history and the phenomenon of anticipation.

Ray M Lowenthal1, Elizabeth M Tegg, Joanne L Dickinson.   

Abstract

We began epidemiological studies of haematological malignancies (lymphomas, leukaemias and related diseases) in Tasmania, the island state of Australia, in 1972. Our work has identified a number of families each containing several cases. In contrast to reports from elsewhere, we recognised familial cases incorporating the range of haematological malignancies, that is, not confined to a single diagnosis. Furthermore the average number of cases per extended family tree has exceeded that of any prior report. An unexpected discovery from the detailed familial analysis was that of anticipation, the phenomenon whereby the symptoms of a disorder become apparent at an earlier age as it is passed on to the next generation. These findings strengthen the case for there being genetic anomalies underlying the development of haematological malignancies at least in some cases, and are the subject of ongoing research.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23968988     DOI: 10.1016/j.transci.2013.07.011

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  2 in total

1.  Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.

Authors:  Nicholas B Blackburn; James R Marthick; Annette Banks; Jac C Charlesworth; Katherine A Marsden; Ray M Lowenthal; John Blangero; Joanne L Dickinson
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

2.  A retrospective examination of mean relative telomere length in the Tasmanian Familial Hematological Malignancies Study.

Authors:  Nicholas B Blackburn; Jac C Charlesworth; James R Marthick; Elizabeth M Tegg; Katherine A Marsden; Velandai Srikanth; John Blangero; Ray M Lowenthal; Simon J Foote; Joanne L Dickinson
Journal:  Oncol Rep       Date:  2014-10-24       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.